SCHEMBL785340

SCHEMBL785340

Cc1cc(N2CCC(CCN(Cc3ccccc3)Cc3ccccc3)CC2)nc(C)n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.47
KMT2A Q03164 3/20 0.47
MEN1 O00255 2/20 0.47
LMNA P02545 2/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
HTT P42858 3/20 0.42
CYP1A2 P05177 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C19 P33261 1/20 0.42
POLB P06746 1/20 0.41
TSHR P16473 2/20 0.41
PKM P14618 1/20 0.41
CRHBP P24387 1/20 0.41
PIK3CB P42338 1/20 0.41
CRHR2 Q13324 1/20 0.41
SORD Q00796 1/20 0.40
TDP1 Q9NUW8 2/20 0.39
ACHE P22303 2/20 0.39
CHRM4 P08173 1/20 0.39
MAPT P10636 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL803660 0.89 ALDH1A1 (0.46) ALDH1A1KMT2AMEN1LMNASMN1; SMN2
SCHEMBL785168 0.75 SORD (0.45) ALDH1A1KMT2AMEN1LMNASMN1; SMN2
SCHEMBL785872 0.74 ACHE (0.46) ACHECHRM4
SCHEMBL22482261 0.72 KDM4E (0.46) ALDH1A1KMT2AMEN1HTTTSHR
SCHEMBL792754 0.70 SORD (0.45) ALDH1A1KMT2AMEN1LMNASMN1; SMN2
SCHEMBL785081 0.69 SIGMAR1 (0.47) ALDH1A1KMT2AMEN1LMNASMN1; SMN2
SCHEMBL785821 0.69 ACHE (0.49) ACHE
SCHEMBL16222432 0.68 SMN1; SMN2 (0.60) ALDH1A1KMT2AMEN1LMNASMN1; SMN2
SCHEMBL784864 0.68 CCR5 (0.51) ALDH1A1KMT2AMEN1LMNASMN1; SMN2
SCHEMBL784769 0.67 HRH3 (0.55) ALDH1A1KMT2AMEN1LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8680159-B2 Bradykinin 1 receptor modulating compounds GRUENENTHAL GMBH (DE) 2014-03-25 US disclosed
EP-2619178-A1 SUBSTITUTED BENZAMIDE COMPOUNDS Grünenthal GmbH (DE) 2013-07-31 EP disclosed
WO-2012038081-A1 SUBSTITUTED BENZAMIDE COMPOUNDS Grünenthal GmbH (DE) 2012-03-29 WO disclosed
WO-2012038081-A1 SUBSTITUTED BENZAMIDE COMPOUNDS Grünenthal GmbH (DE) 2012-03-29 WO disclosed
US-20120071461-A1 Substituted Benzamide Compounds GRUENENTHAL GMBH (DE) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071461-A1 Substituted Benzamide Compounds BDKRB1, BDKRB2, HRH2 ALDH1A1 1267/4885KMT2A 2222/4885MEN1 2563/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.